Benefit–risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty

References

• Preventing Venous Thromboembolic Disease in Patients Undergoing Elective Hip and Knee Arthroplasty: Evidence-Based Guideline and Evidence ReportRosemont, ILAmerican Academy of Orthopaedic Surgeons2011 Available from: http://www.aaos.org/research/guidelines/VTE/VTE_full_guideline.pdfAccessed October 1, 2013
   Google Scholar
• KearonCNatural history of venous thromboembolismCirculation200310723 Suppl 1I22I3012814982
   PubMed Web of Science ®Google Scholar
• KahnSRHirschAShrierIEffect of postthrombotic syndrome on health-related quality of life after deep venous thrombosisArch Intern Med2002162101144114812020185
   PubMedGoogle Scholar
• KahnSRGinsbergJSRelationship between deep venous thrombosis and the postthrombotic syndromeArch Intern Med20041641172614718318
   PubMed Web of Science ®Google Scholar
• LangIKerrKRisk factors for chronic thromboembolic pulmonary hypertensionProc Am Thorac Soc20063756857016963535
   PubMedGoogle Scholar
• PengoVLensingAWAPrinsMHThromboembolic Pulmonary Hypertension Study Group. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolismN Engl J Med2004350222257226415163775
   PubMed Web of Science ®Google Scholar
• EikelboomJWKarthikeyanGFagelNHirshJAmerican Association of Orthopedic Surgeons and American College of Chest Physicians guidelines for venous thromboembolism prevention in hip and knee arthroplasty differ: what are the implications for clinicians and patients?Chest2009135251352019201714
   PubMed Web of Science ®Google Scholar
• Falck-YtterYFrancisCWJohansonNAAmerican College of Chest Physicians. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesChest2012141Suppl 2e278Se325S22315265
   PubMed Web of Science ®Google Scholar
• WarwickDFriedmanRJAgnelliGInsufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic RegistryJ Bone Joint Surg Br200789679980717613508
   PubMedGoogle Scholar
• AgenoWGallusASWittkowskyACrowtherMHylekEMPalaretiGAmerican College of Chest Physicians. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis. 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesChest2012141Suppl 2e44Se88S22315269
   PubMed Web of Science ®Google Scholar
• ErikssonBIBorrisLCFriedmanRJRECORD1 Study GroupRivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplastyN Engl J Med2008358262765277518579811
   PubMed Web of Science ®Google Scholar
• KakkarAKBrennerBDahlOERECORD2 InvestigatorsExtended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trialLancet20083729632313918582928
   PubMed Web of Science ®Google Scholar
• LassenMRAgenoWBorrisLCRECORD3 InvestigatorsRivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplastyN Engl J Med2008358262776278618579812
   PubMed Web of Science ®Google Scholar
• TurpieAGGLassenMRDavidsonBLRECORD4 InvestigatorsRivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trialLancet200937396761673168019411100
   PubMed Web of Science ®Google Scholar
• TurpieAGGLassenMRErikssonBIRivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studiesThromb Haemost2011105344445321136019
   PubMed Web of Science ®Google Scholar
• CoplanPMNoelRALevitanBSFergusonJMussenFDevelopment of a framework for enhancing the transparency, reproducibility and communication of the benefit-risk balance of medicinesClin Pharmacol Ther201189231231521160469
   PubMed Web of Science ®Google Scholar
• Benefit-risk methodology [webpage on the Internet]LondonEuropean Medicines Agency2011 Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/document_listing/document_listing_000314.jsp&mid=WC0b01ac0580223ed6&murl=menus/special_topics/special_topics.jsp&jsenabled=trueAccessed July 16, 2013
   Google Scholar
• LevitanBSAndrewsEBGilsenanAApplication of the BRAT framework to case studies: observations and insightsClin Pharmacol Ther201189221722421178990
   PubMed Web of Science ®Google Scholar
• Structured Approach to Benefit-Risk Assessment in drug Regulatory Decision-MakingUS Food and Drug Administration2013 Available from: http://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM329758.pdfAccessed September 2, 2013
   Google Scholar
• Benefit-risk integration and representation [webpage on the Internet]PROTECT Investigators Innovative Medicines Initiative Available from: http://www.imi-protect.eu/benefitPres.shtmlAccessed July 16, 2013
   Google Scholar
• WalkerSLibertiLMcAuslaneNLevitanBSRefining the benefit-risk framework for the assessment of medicines: valuing and weighting benefit and risk parametersClin Pharmacol Ther201189217918221252937
   PubMed Web of Science ®Google Scholar
• BauerKATurpieAGGLassenMRKakkarAKErikssonBIGentMRECORD 1–4 InvestigatorsEffects of age, weight, gender and renal function in a pooled analysis of four rivaroxaban studiesJ Thromb Haemost20097S2767 PP-WE-421
   Google Scholar
• ErikssonBIKakkarAKTurpieAGGOral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacementJ Bone Joint Surg Br200991563664419407299
   PubMedGoogle Scholar
• BeasleyBNUngerEFTempleRAnticoagulant options – why the FDA approved a higher but not a lower dose of dabigatranN Engl J Med2011364191788179021488759
   PubMed Web of Science ®Google Scholar
• GibsonCMLevitanBMurphySAA net clinical outcome analysis comparing fatal or irreversible ischemic and bleeding events in ATLAS ACS 2 – TIMI 51Circulation2012126A13152
   Web of Science ®Google Scholar
• HullRDYusenRDBergqvistDState-of-the-art review: assessing the safety profiles of new anticoagulants for major orthopedic surgery thromboprophylaxisClin Appl Thromb Hemost200915437738819608549
   PubMed Web of Science ®Google Scholar
• KaulSDiamondGADoes rivaroxaban provide a clinically relevant favorable benefit-risk profile compared with enoxaparin after hip or knee arthroplasty?J Am Coll Cardiol20105510E1616E1618A172
   Google Scholar
• LevitanBYuanZTurpieAGGQuantitative benefit–risk assessment of rivaroxaban for the prevention of venous thromboembolismBlood (ASH Annual Meeting Abstracts)2009114227576 A169
   Web of Science ®Google Scholar
• SingerDEChangYFangMCThe net clinical benefit of warfarin anticoagulation in atrial fibrillationAnn Intern Med2009151529730519721017
   PubMed Web of Science ®Google Scholar
• UngerEFWeighing benefits and risks – the FDA’s review of prasugrelN Engl J Med20093611094294519726770
   PubMed Web of Science ®Google Scholar
• Van ThielDKalodikiEWahiRLitinasEHaqueWRaoGInterpretation of benefit-risk of enoxaparin as comparator in the RECORD program: rivaroxaban oral tablets (10 milligrams) for use in prophylaxis in deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee replacement surgeryClin Appl Thromb Hemost200915438939419608550
   PubMed Web of Science ®Google Scholar
• Gómez-OutesATerleira-FernándezAISuárez-GeaMLVargas-CastrillónEDabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisonsBMJ2012344e367522700784
   PubMed Web of Science ®Google Scholar
• Advisory Committee Briefing Book: Rivaroxaban for the Prophylaxis of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Patients Undergoing Hip or Knee Replacement SurgeryJohnson & Johnson Pharmaceutical Research and Development, LLC2009 Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM138385.pdfAccessed September 2, 2013
   Google Scholar
• LassenMRGentMKakkarAKThe effects of rivaroxaban on the complications of surgery after total hip or knee replacement: results from the RECORD programmeJ Bone Joint Surg Br201294111573157823109641
   PubMedGoogle Scholar
• CushnerFAgnelliGFitzGeraldGWarwickDComplications and functional outcomes after total hip arthroplasty and total knee arthroplasty: results from the Global Orthopaedic Registry (GLORY)Am J Orthop (Belle Mead NJ)201039Suppl 9222821290028
   PubMedGoogle Scholar
• JamesonSSRymaszewskaMJamesPWound complications following rivaroxaban administration: a multicenter comparison with low-molecular-weight heparins for thromboprophylaxis in lower limb arthroplastyJ Bone Joint Surg Am201294171554155822832942
   PubMed Web of Science ®Google Scholar
• JensenCDStevalAPartingtonPFReedMRMullerSDReturn to theatre following total hip and knee replacement, before and after the introduction of rivaroxaban: a retrospective cohort studyJ Bone Joint Surg Br2011931919521196550
   PubMedGoogle Scholar
• ChanCMZilberbergMDPreferences in traumatic intracranial hemorrhage: bleeding vs. clottingCrit Care201014315320497598
   PubMed Web of Science ®Google Scholar
• LipGYHPiotrponikowskiPAndreottiFThromboembolism and antithrombotic therapy for heart failure in sinus rhythm. An Executive Summary of a joint Consensus Document from the ESC Heart Failure Association and the ESC Working Group on ThrombosisThromb Haemost201210861009102223093044
   PubMed Web of Science ®Google Scholar